Literature DB >> 26436358

The burden of cirrhosis and impact of universal coverage public health care system in Thailand: Nationwide study.

Kittiyod Poovorawan1, Sombat Treeprasertsuk2, Kaewjai Thepsuthammarat3, Polrat Wilairatana1, Bubpha Kitsahawong4, Kamthorn Phaosawasdi4.   

Abstract

BACKGROUND AND RATIONALE: Cirrhosis is responsible for significant health-care costs and morbidity. This study aims to evaluate the burden of illness associated with cirrhosis, its impact on the universal coverage public health care system in Thailand.
MATERIAL AND METHODS: We used data from the 2010 Nationwide Hospital Admission Data, the National Health Security Office (NHSO), Thailand. Their baseline characteristics, hospital costs, and outcomes were analyzed according to national health insurance categories including medical welfare scheme (MWFS), social security scheme (SSS) and civil servant medical benefit scheme (CSMBS).
RESULTS: 92,301 admissions were eligible for analysis. The mean age was 55 ± 12.8 years, and 63.3% of patients were above 50 years old. The majority of patients (79%) belonged to the MWFS group. The MWFS group incurred the lowest medical expense and had the shortest hospital stay compared to the SSS and CSMBS groups. Overall in-hospital mortality was 10.7%. Cirrhosis complications include bleeding esophageal varices, spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, and hepatocellular carcinoma. These complications significantly increased mortality rates compared to patients without complications (26 vs. 8.9%, p < 0.001). In-hospital mortality of patients with cirrhosis complications did not differ among the three national health insurance groups. Respiratory failure and septicemia were associated with the highest risk of death (HR 5.4; 95% CI: 4.8-5.9 and HR 5.2; 95% CI: 4.9-5.6 respectively; P < 0.001).
CONCLUSIONS: Illness associated with cirrhosis is a significant public health problem in Thailand. Outcomes of cirrhosis complications did not differ between universal public health care coverage systems in Thailand.

Entities:  

Mesh:

Year:  2015        PMID: 26436358     DOI: 10.5604/16652681.1171773

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  8 in total

1.  Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand.

Authors:  Bunchai Chongmelaxme; Pochamana Phisalprapa; Ratree Sawangjit; Piyameth Dilokthornsakul; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

2.  Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand.

Authors:  Pochamana Phisalprapa; Ratthanon Prasitwarachot; Chayanis Kositamongkol; Pranaidej Hengswat; Weerachai Srivanichakorn; Chaiwat Washirasaksiri; Sombat Treeprasertsuk; Phunchai Charatcharoenwitthaya; Nathorn Chaiyakunapruk
Journal:  BMC Gastroenterol       Date:  2021-03-25       Impact factor: 3.067

3.  A significant cancer burden and high mortality of intrahepatic cholangiocarcinoma in Thailand: a nationwide database study.

Authors:  Sombat Treeprasertsuk; Kittiyod Poovorawan; Ngamphol Soonthornworasiri; Roongruedee Chaiteerakij; Kessarin Thanapirom; Pisaln Mairiang; Kookwan Sawadpanich; Kanokwan Sonsiri; Varocha Mahachai; Kamthorn Phaosawasdi
Journal:  BMC Gastroenterol       Date:  2017-01-05       Impact factor: 3.067

4.  In Response.

Authors:  Kittiyod Poovorawan
Journal:  Am J Trop Med Hyg       Date:  2017-03       Impact factor: 2.345

5.  Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.

Authors:  Guy Neff; Woodie Zachry
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

6.  Serological evidence of hepatitis A, B, and C virus infection in older adults in Khon Kaen, Thailand and the estimated rates of chronic hepatitis B and C virus infection in Thais, 2017.

Authors:  Nawarat Posuwan; Viboonsak Vuthitanachot; Teeraporn Chinchai; Rujipat Wasitthankasem; Nasamon Wanlapakorn; Yong Poovorawan
Journal:  PeerJ       Date:  2019-08-19       Impact factor: 2.984

7.  Knowledge, attitude, and behaviors toward liver health and viral hepatitis-related liver diseases in Thailand.

Authors:  Pochamana Phisalprapa; Tawesak Tanwandee; Boon-Leong Neo; Shikha Singh
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

8.  Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome.

Authors:  Sermsiri Sangroongruangsri; Kankamon Kittrongsiri; Phunchai Charatcharoenwitthaya; Abhasnee Sobhonslidsuk; Usa Chaikledkaew
Journal:  Clinicoecon Outcomes Res       Date:  2021-07-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.